Relationship between low levels of circulating TRAIL and atheromatosis progression in patients with chronic kidney disease
Open Access
- 11 September 2018
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (9) , e0203716
Abstract
Chronic kidney disease (CKD) patients experience a high risk of cardiovascular disease (CV); however, the factors involved in CV-related morbidity and mortality in these patients have not been fully defined. Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a cytokine, which exhibits pleiotropic activities on endothelial, vascular smooth muscle and inflammatory cells, with relevant effects on atheromatous plaque formation. On this basis, the present study aims to investigate the role of TRAIL in atheromatosis progression in CKD patients. Circulating TRAIL levels were measured in 378 CKD patients belonging to the Spanish National Observatory of Atherosclerosis in Nephrology (NEFRONA) study. All patients were free of previous CV events. Carotid and femoral B-mode ultrasound was performed to detect the presence of plaque at baseline and after 24 months of follow-up. The lowest levels of TRAIL at baseline were significantly (p<0.05) associated with the appearance, after 24 months of follow-up, of at least two new atheromatous plaques in all territories and of one new plaque in the carotid artery, even after adjusting for CV risk factors. In addition, the patients with low levels of TRAIL at baseline were characterized by the presence of at least one hypoechoic plaque in the carotid artery. This association was significant (p<0.05) even after adjusting for CKD stage. Overall, the results of our study suggest TRAIL as an assertable independent prognostic biomarker for atheromatosis plaque formation in CKD patients. This observation further supports the potential role of TRAIL for the prevention/treatment of CV disease.Keywords
Funding Information
- Ministero della Salute (GR-2013-02358192)
- AbbVie
- Spanish government RETIC (RD16/0009/0011)
- Spanish government FIS (PI16/01354)
- Associazione Italiana per la Ricerca sul Cancro (18055)
This publication has 45 references indexed in Scilit:
- Redox signaling and oxidative stress: Cross talk with TNF-related apoptosis inducing ligand activityThe International Journal of Biochemistry & Cell Biology, 2016
- Serum TRAIL levels increase shortly after insulin therapy and metabolic stabilization in children with type 1 diabetes mellitusActa Diabetologica, 2015
- The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirementActa Diabetologica, 2013
- TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe −/− miceDiabetologia, 2011
- TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient miceAtherosclerosis, 2011
- Association of tumor necrosis factor-related apoptosis-inducing ligand with total and cardiovascular mortality in older adultsAtherosclerosis, 2011
- Statins reduce endothelial cell apoptosis via inhibition of TRAIL expression on activated CD4 T cells in acute coronary syndromeAtherosclerosis, 2010
- An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarctionAtherosclerosis, 2010
- Expression, regulation and function of trail in atherosclerosisBiochemical Pharmacology, 2008
- TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cellsCellular and Molecular Life Sciences, 2004